Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
Revive Therapeutics (OTCQB: RVVTF) has announced a proposed private placement offering of up to 30,952,381 units at $0.021 per unit, aiming to raise gross proceeds of up to $650,000. Additionally, the company plans to settle a $67,400 debt through the issuance of 3,209,523 units at the same price.
Each unit includes one common share and one warrant, with warrants exercisable at $0.05 per share for 36 months. The proceeds will be used for working capital and trade payables. The offering may close in multiple tranches, with securities subject to a four-month hold period.
Revive Therapeutics (OTCQB: RVVTF) ha annunciato un'offerta privata proposta di un massimo di 30.952.381 unità a 0,021$ per unità, con l'obiettivo di raccogliere proventi lordi fino a 650.000$. Inoltre, la società intende estinguere un debito di 67.400$ tramite l'emissione di 3.209.523 unità allo stesso prezzo.
Ogni unità comprende una azione ordinaria e una warrant, con warrant esercitabili a 0,05$ per azione per 36 mesi. I proventi saranno utilizzati per il capitale circolante e i debiti commerciali. L'offerta può chiudersi in più tranche, con i titoli soggetti a un periodo di blocco di quattro mesi.
Revive Therapeutics (OTCQB: RVVTF) ha anunciado una oferta privada propuesta de hasta 30.952.381 unidades a 0,021$ por unidad, con el objetivo de recaudar ingresos brutos de hasta 650.000$. Además, la compañía planea saldar una deuda de 67.400$ mediante la emisión de 3.209.523 unidades al mismo precio.
Cada unidad incluye una acción común y una warrant, con warrants ejercitables a 0,05$ por acción durante 36 meses. Los ingresos se utilizarán para capital de trabajo y cuentas por pagar comerciales. La oferta puede cerrarse en múltiples tramos, con valores sujetos a un período de retención de cuatro meses.
Revive Therapeutics (OTCQB: RVVTF)는 최대 30,952,381 단위, 단위당 0.021달러의 사모 발행을 제안했으며, 최대 650,000달러의 총 수익을 목표로 하고 있습니다. 또한 회사는 67,400달러 부채를 동일한 가격으로 3,209,523 단위 발행을 통해 상환할 계획입니다.
각 단위는 보통주 1주와 워런트 1주로 구성되며, 워런트는 36개월 동안 주당 0.05달러에 행사 가능합니다. 수익금은 운전자본 및 상거래 채무 상환에 사용될 예정입니다. 이 제안은 여러 차수로 마감될 수 있으며, 증권은 4개월의 보유 기간이 적용됩니다.
Revive Therapeutics (OTCQB : RVVTF) a annoncé une offre privée proposée de jusqu'à 30 952 381 unités à 0,021 $ par unité, visant à lever des produits bruts allant jusqu'à 650 000 $. De plus, la société prévoit de régler une dette de 67 400 $ par l'émission de 3 209 523 unités au même prix.
Chaque unité comprend une action ordinaire et un bon de souscription, les bons étant exerçables à 0,05 $ par action pendant 36 mois. Les produits seront utilisés pour le fonds de roulement et les dettes commerciales. L'offre peut être clôturée en plusieurs tranches, les titres étant soumis à une période de blocage de quatre mois.
Revive Therapeutics (OTCQB: RVVTF) hat ein geplantes Privatplatzierungsangebot von bis zu 30.952.381 Einheiten zu je 0,021$ angekündigt, mit dem Ziel, Bruttoerlöse von bis zu 650.000$ zu erzielen. Zusätzlich plant das Unternehmen, eine Schuld in Höhe von 67.400$ durch die Ausgabe von 3.209.523 Einheiten zum gleichen Preis zu begleichen.
Jede Einheit umfasst eine Stammaktie und eine Optionsanleihe, wobei die Optionsanleihen zu 0,05$ pro Aktie für 36 Monate ausübbar sind. Die Erlöse werden für das Betriebskapital und Handelsverbindlichkeiten verwendet. Das Angebot kann in mehreren Tranchen abgeschlossen werden, wobei die Wertpapiere einer viermonatigen Haltefrist unterliegen.
- Debt settlement of $67,400 helps preserve cash for operations
- Warrant exercise price of $0.05 represents potential 138% premium to unit price
- Flexible closing structure allows for multiple tranches
- Significant dilution through issuance of up to 34,161,904 new units
- Low unit price of $0.021 indicates challenging market conditions
- Additional dilution possible if warrants are exercised
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is proposing to arrange a private placement offering of up to 30,952,381 units, at a price of
Each unit will consist of one common share of the Company and one common share purchase warrant. Each warrant will entitle the holder to acquire one common share at an exercise price of
The gross proceeds from the private placement offering will be used for working capital and payment of certain trade payables. The proposed private placement may close in one or more tranches.
The Company believes that it is desirable to settle the outstanding note payable by the issuance of securities in order to preserve the Company’s cash for ongoing operations.
Closing of the private placement and the debt settlement is subject to customary closing conditions and the Company intends to close as soon as practicable. All of the securities will be subject to a hold period of four months and one day from the date of issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company's management's discussion and analysis for the three and nine months ended March 31, 2025 ("MD&A"), dated May 29, 2025, which is available on the Company's profile at www.sedarplus.ca.
FAQ
What is the size and price of Revive Therapeutics (RVVTF) private placement offering?
How will RVVTF use the proceeds from the private placement?
What are the terms of the warrants in Revive Therapeutics' private placement?
How much debt is Revive Therapeutics settling through unit issuance?
What is the hold period for securities issued in RVVTF's private placement?
